Advanced Member
Posted 27 July 2017 - 09:47 PM
http://www.lifescien...validation-2322
"A European Patent Office (EPO) Board of Appeal has published its decision that invalidated a patent owned by Bristol-Myers Squibb (BMS) which covered a blockbuster anti-cancer drug.
Published on Monday, July 24, the decision invalidated European Patent number 1169038, a composition-of-matter patent covering dasatinib."
Diagnosed 11 May 2011 (100% FiSH, 155% PCR)
with b2a2 BCR-ABL fusion transcript coding for the 210kDa BCR-ABL protein
Sprycel: 20 mg per day - taken at lights out with Quercetin and/or Magnesium Taurate
6-8 grams Curcumin C3 complex.
2015 PCR: < 0.01% (M.D. Anderson scale)
2016 PCR: < 0.01% (M.D. Anderson scale)
March 2017 PCR: 0.01% (M.D. Anderson scale)
June 2017 PCR: "undetected"
September 2017 PCR: "undetected"
0 members, 1 guests, 0 anonymous users
